Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci195725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Simon Garinet und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, and. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Translocation, Genetic, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Doris Duke Charitable Foundation, Department of Defense Kidney Cancer Research Program.
Abstract (Originalsprache)
TFE3 translocation renal cell carcinoma (tRCC), an aggressive kidney cancer driven by TFE3 gene fusions, is frequently misdiagnosed owing to morphologic overlap with other kidney cancer subtypes. Conventional liquid biopsy assays that detect tumor DNA via somatic mutations or copy number alterations are unsuitable for tRCC since it often lacks recurrent genetic alterations and because fusion breakpoints are highly variable between patients. We reasoned that epigenomic profiling could more effectively detect tRCC because the driver fusion constitutes an oncogenic transcription factor that alters gene regulation. By defining a TFE3-driven epigenomic signature in tRCC cell lines and detecting it in patient plasma using ChIP-seq, we distinguished tRCC from clear-cell RCC (AUC = 0.86) and samples of individuals without evidence of cancer (AUC = 0.92) at low tumor fractions (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, and.
- Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Förderung
- NCI NIH HHS
- Doris Duke Charitable Foundation
- Department of Defense Kidney Cancer Research Program
- Rally Foundation Independent Investigator Award
- National Foundation for Cancer Research
- V Foundation
- NCI
- DF/HCC Kidney SPORE DRP
Zitieren
APA
Garinet, S., Semaan, K., Li, J., Zhang, Z., Konda, P., Sadagopan, A., Canniff, J., Phillips, N., Klega, K., Pandey, M., Savignano, H., Davidsohn, M. P., Lyons, K., Medda, A., Khanna, P., Achom, M., Fortunato, B. J., Nawfal, R., El Hajj Chehade, R., …, & Viswanathan, S. R. (2026). Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma. Journal of Clinical Investigation. https://doi.org/10.1172/jci195725
Vancouver
Garinet S, Semaan K, Li J, Zhang Z, Konda P, Sadagopan A, et al. Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma. Journal of Clinical Investigation. 2026. doi:10.1172/jci195725
BibTeX
@article{Garinet2026,
author = {Garinet, Simon and Semaan, Karl and Li, Jiao and Zhang, Ze and Konda, Prathyusha and Sadagopan, Ananthan and Canniff, John and Phillips, Noa and Klega, Kelly and Pandey, Medha and Savignano, Hunter and Davidsohn, Matthew P and Lyons, Kevin and Medda, Alessandro and Khanna, Prateek and Achom, Mingkee and Fortunato, Brad J and Nawfal, Rashad and El Hajj Chehade, Razane and O'Toole, Jillian and Horst, Jack and Freeman, Dory and Trowbridge, Rachel and Chau, Cindy H and Figg, William D and Berchuck, Jacob E and Crompton, Brian D and Seo, Ji-Heui and Choueiri, Toni K and Freedman, Matthew L and Baca, Sylvan C and Viswanathan, Srinivas R},
title = {Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci195725}
}
EUVIMED